• Researcher Profile

    David A. Barbie, MD


    Assistant Professor of Medicine, Harvard Medical School


    Thoracic Oncology

    Office phone: 617-632-6049
    Fax: 617-632-5786
    Website: The Barbie Lab

    Preferred contact method: office phone

    View Physician Profile


    Lung cancer, Translational oncology, KRAS targeted therapy

    Area of Research

    Translational Oncology/KRAS Targeted Therapy

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

    Recent Awards

    • NIH R01 Award, 2015
    • V Foundation Scholar Award, 2012
    • NIH K08 Award, 2010
    • ASCO Young Investigator Award, 2009


    Translational Oncology/KRAS Targeted Therapy

    My interest as a medical oncologist and cancer biologist is to identify novel targets for cancer therapy. Specifically, I have focused on lung cancer clinically with a particular interest in targeting KRAS mutations, which have remained refractory to current therapies.

    We previously found that TBK1, a kinase that is normally involved in immune cell signaling, prevents apoptosis in cancer cells driven by oncogenic KRAS. Others have found that inhibition of the NF-kB and STAT pathways, in which TBK1 is involved, also results in impaired tumor growth in KRAS-driven mouse lung cancer. Recently, we discovered that a kinase inhibitor, momelotinib, inhibits TBK1 and JAK signaling and has activity in mouse models of Kras-driven lung cancer. Based on these findings, we have opened a trial together with Gilead Sciences combining momelotinib with the MEK inhibitor trametinib in treatment refractory KRAS mutant lung cancer.

    My overall goal is to continue this effort clinically and in the lab to refine combination therapy for KRAS-driven lung cancer and improve outcomes for this challenging disease.

View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer

Give Now